Physician profile
Haoxing Jin
NPI 1750822177
$2,841.99
in general payments reported to CMS, 2019-2025
18 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $72.93 · 2021: $77.81 · 2023: $73.25 · 2024: $578 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $309.25 | 2019-2025 | Idosetr |
| Alcon Vision LLC | $297.10 | 2019-2025 | Hydrus Microstent, Rocklatan, Rhopressa |
| Genentech USA, INC. | $293.23 | 2023-2025 | Vabysmo, Susvimo |
| Dutch Ophthalmic, USA | $289.14 | 2025 | Tissueblue, Eva, Combined Machine |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $246.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $227.97 | 2023-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $218.86 | 2024-2025 | Xiidra, Miebo |
| Astellas Pharma US INC | $159.29 | 2024-2025 | Izervay |
| Amgen INC. | $158.85 | 2025 | Tepezza |
| Abbvie INC. | $125.19 | 2024-2025 | |
| Alimera Sciences, INC. | $102.68 | 2023-2024 | Iluvien, Yutiq |
| Sun Pharmaceutical Industries INC. | $96.20 | 2025 | |
| Ani Pharmaceuticals, INC. | $81.08 | 2025 | Purified Cortrophin Gel, Yutiq |
| Ocular Therapeutix, INC. | $77.17 | 2024-2025 | Dextenza |
| Dompe US, INC. | $66.61 | 2024-2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $46.25 | 2024-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $28.01 | 2025 | Acthar |
| Merz North America, INC. | $18.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haoxing Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.